According to a new market research report published by Global Market Estimates, the Global Adeno-Associated Viral Vector Manufacturing Market is projected to grow at a CAGR value of 22.9% from 2022 and 2027.

Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Adeno-Associated Viral Vector Manufacturing Market - Forecast to 2027" https://www.globalmarketestimates.com/market-report/adeno-associated-viral-vector-manufacturing-market-3736

 Biomarin Pharmaceutical, Sarepta Therapeutics, Roche (Spark Therapeutics), Sangamo, Pfizer, NightstaRx, Freeline Therapeutics, Horama S.A, MeiraGTx, RegenxBio, Asklepios Biopharmaceutical, and Audentes Therapeutics, among others, are the key players in the adeno-associated viral vector manufacturing market.

 

Type Outlook (Revenue, USD Million, 2022-2027)

·         Single-stranded AAV (ssAAV)

·         Self-complementary AAV (scAAV)

Application Outlook (Revenue, USD Million, 2022-2027)

·         Hemophilia

·         Ophthalmology

·         Lysosomal Storage Disorders

·         Neurological Disorders

·         Others

Regional Outlook (Revenue, USD Million, 2022-2027)

North America                                                                                 

• The U.S.
• Canada
• Mexico

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC

 Central & South America

• Brazil
• Argentina
• Rest of CSA

Middle East & Africa

• Saudi Arabia
• UAE
• Rest of MEA

 

 

Contact: Yash Jain

Email address: yash.jain@globalmarketestimates.com

Phone Number: +16026667238